Trial Profile
A Double Blind Comparison of Omacor and Placebo as Secondary Prevention Against Cardiovascular Events in Patients Undergoing Chronic Hemodialysis.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Dec 2008
Price :
$35
*
At a glance
- Drugs Omega-3-acid ethyl esters (Primary)
- Indications Cardiovascular disorders
- Focus Therapeutic Use
- Sponsors Pronova BioPharma
- 12 Dec 2008 New trial record.